Evidence map›Paper›PMID 26555887›Full record

ArticleActa neuropathologica communications2015

Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains.

Jonathan Janssens, Stéphanie Philtjens, Gernot Kleinberger, Sara Van Mossevelde, Julie van der Zee, Rita Cacace, Sebastiaan Engelborghs, Anne Sieben, Julia Banzhaf-Strathmann, Lubina Dillen and 16 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. The Role of Z-disc Proteins in Myopathy and Cardiomyopathy.International journal of molecular sciences · 2021
    Review
  3. Review
  4. Structure and Function of Filamin C in the Muscle Z-Disc.International journal of molecular sciences · 2020
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Jonathan JanssensNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. jonathan.janssens@molgen.vib-ua.be.
Stéphanie PhiltjensNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. Stephanie.Philtjens@molgen.vib-ua.be.
Gernot KleinbergerNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. Gernot.Kleinberger@mail03.med.uni-muenchen.de.
Sara Van MosseveldeNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. Sara.VanMossevelde@molgen.vib-ua.be.
Julie van der ZeeNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. julie.vanderzee@molgen.vib-ua.be.
Rita CacaceNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. rita.cacace@molgen.vib-ua.be.
Sebastiaan EngelborghsInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium. sebastiaan.engelborghs@uantwerpen.be.
Anne SiebenNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. annesieben@yahoo.com.
Julia Banzhaf-StrathmannGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany. julia.banzhaf@dzne.lmu.de.
Lubina DillenNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. lubina.dillen@molgen.vib-ua.be.
Céline MerlinNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. celine.merlin@molgen.vib-ua.be.
Ivy CuijtNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. ivy.cuijt@molgen.vib-ua.be.
Caroline RobberechtNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. caroline.robberecht@molgen.vib-ua.be.
Bettina SchmidGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany. bettina.schmid@med.uni-muenchen.de.
Patrick SantensDepartment of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium. Patrick.Santens@UGent.be.
Adrian IvanoiuDepartment of Neurology, Saint-Luc University Hospital and Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium. adrian.ivanoiu@uclouvain.be.
Mathieu VandenbulckeDepartment of Neurosciences, Faculty of Medicine, KU Leuven, Leuven, Belgium. mathieu.vandenbulcke@uz.kuleuven.ac.be.
Rik VandenbergheDepartment of Neurosciences, Faculty of Medicine, KU Leuven, Leuven, Belgium. rik.vandenberghe@uz.kuleuven.ac.be.
Patrick CrasInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium. patrick.cras@uantwerpen.be.
Peter P De DeynInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium. p.p.de.deyn@umcg.nl.
Jean-Jacques MartinInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium. jean-jacques.martin@uantwerpen.be.
Stuart MaudsleyInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium. Stuart.Maudsley@molgen.vib-ua.be.
Christian HaassGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany. chaass@med.uni-muenchen.de.
Marc CrutsNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. marc.cruts@molgen.vib-ua.be.
Christine Van BroeckhovenNeurodegenerative Brain Diseases group, VIB Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1, B-2610, Antwerp, Belgium. christine.vanbroeckhoven@molgen.vib-ua.be.
Belgian Neurology (BELNEU) consortium
University of Antwerp · BEVIB-UAntwerp Center for Molecular Neurology · BEGerman Center for Neurodegenerative Diseases · DEKU Leuven · BEGhent University Hospital · BEUCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAR DNA-binding protein 43 (TDP-43) inclusions are pathological hallmarks of patients with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Loss of TDP-43 in zebrafish engenders a severe muscle and vascular phenotype with a concomitant elevation of filamin C (FLNC) levels, an observation confirmed in the frontal cortex of FTLD-TDP patients. Here, we aimed to further assess the contribution of FLNC to frontotemporal dementia (FTD) etiology. We conducted a mutational screening of FLNC in a cohort of 529 unrelated Belgian FTD and FTD-ALS patients, and a control cohort of 920 unrelated and age-matched individuals. Additionally we performed an in-depth characterization of FLNC expression levels in FTD patients and a murine FTD model.In total 68 missense variants were identified of which 19 (MAF < 1%) were patient-only. Gene burden analysis demonstrated a significant association between the presence of rare variants in FLNC and disease (P = 0.0349, RR = 1.46 [95% CI 1.03-2.07]). Furthermore, elevated FLNC expression levels, observed previously in FTLD-TDP patients, were mainly attributable to FTD patients with the progranulin (GRN) p.0(IVS1 + 5G > C) loss-of-function mutation. Increased FLNC levels were, to a lesser extent, also identified in a FLNC p.V831I variant carrier and in FTD patients with the p.R159H mutation in valosin-containing protein (VCP). The GRN-associated increase of FLNC was confirmed in the frontal cortex of aged Grn knockout mice starting at 16-18 months of age. Combined quantitative proteomic and bioinformatic analyses of the frontal cortex of FTD patients possessing elevated FLNC levels, identified multiple altered protein factors involved in accelerated aging, neurodegeneration and synaptogenesis.Our findings further support the involvement of aberrant FLNC expression levels in FTD pathogenesis. Identification of increased FLNC levels in aged Grn mice and impaired pathways related to aging and neurodegeneration, implies a potential role for FLNC in mediating or accelerating the aging process.

Indexed as

AdultAgedAnimalsBelgiumCase-Control StudiesCell Line, TransformedCohort StudiesDNA-Binding ProteinsFemaleFilaminsFrontal LobeFrontotemporal DementiaGene Expression RegulationHumansImmunoprecipitationIntercellular Signaling Peptides and ProteinsDNA-Binding ProteinsFilaminsGRN protein, humanIntercellular Signaling Peptides and ProteinsProgranulins

Identifiers

PMID26555887
PMCPMC4641381
OpenAlexW2191052126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.